SALT LAKE CITY, May 11, 2023 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update. First…Read More
Lipocine Announces Financial Results for the First Quarter Ended March 31 2023
